139 Efficacy and Safety of a Topical inflammasome inhibitor targeting GPCR19 Agonist in Mild-to-Moderate Atopic Dermatitis: Results from Phase 2 Studies
Journal of Investigative Dermatology · 2025-11 · 145 (11) · e54
DOI: 10.1016/j.jid.2025.09.154 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2025-11. Verfasst von Seung-Yong Seong und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Seong, S., Baek, G. H., Jun, S., Groysman, V., & Na, J. (2025). 139 Efficacy and Safety of a Topical inflammasome inhibitor targeting GPCR19 Agonist in Mild-to-Moderate Atopic Dermatitis: Results from Phase 2 Studies. Journal of Investigative Dermatology, 145(11), e54. https://doi.org/10.1016/j.jid.2025.09.154
Vancouver
Seong S, Baek GH, Jun S, Groysman V, Na J. 139 Efficacy and Safety of a Topical inflammasome inhibitor targeting GPCR19 Agonist in Mild-to-Moderate Atopic Dermatitis: Results from Phase 2 Studies. Journal of Investigative Dermatology. 2025;145(11):e54. doi:10.1016/j.jid.2025.09.154
BibTeX
@article{Seong2025,
author = {Seong, Seung-Yong and Baek, Gyeong Ho and Jun, Soojin and Groysman, Vlada and Na, Jung-Im},
title = {139 Efficacy and Safety of a Topical inflammasome inhibitor targeting GPCR19 Agonist in Mild-to-Moderate Atopic Dermatitis: Results from Phase 2 Studies},
journal = {Journal of Investigative Dermatology},
year = {2025},
volume = {145},
number = {11},
pages = {e54},
doi = {10.1016/j.jid.2025.09.154}
}
EUVIMED